Country: Canada
Language: English
Source: Health Canada
RITONAVIR
ABBVIE CORPORATION
J05AE03
RITONAVIR
80MG
SOLUTION
RITONAVIR 80MG
ORAL
240ML(1BTLE)
Prescription
HIV PROTEASE INHIBITORS
Active ingredient group (AIG) number: 0128780002; AHFS:
CANCELLED POST MARKET
2019-03-31
_ _ _NORVIR Product Monograph _ _Page 1 of 72 _ _Date of Revision: February 27, 2019 and Control No. _ PRODUCT MONOGRAPH PR NORVIR ® Ritonavir film-coated tablets (100 mg) PR NORVIR ® Ritonavir oral solution (80 mg/mL) Human Immunodeficiency Virus (HIV) Protease Inhibitor Date of Initial Approval: August 9, 1996 Date of Previous Revision: September 25, 2018 AbbVie Corporation Date of Revision: 8401 Trans-Canada Highway May 15, 2019 St-Laurent, Qc H4S 1Z1 Submission Control No: 225125 _ _ _NORVIR Product Monograph _ _Page 2 of 72 _ _Date of Revision: February 27, 2019 and Control No. _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................6 ADVERSE REACTIONS ..................................................................................................14 DRUG INTERACTIONS ..................................................................................................23 DOSAGE AND ADMINISTRATION ..............................................................................42 OVERDOSAGE ................................................................................................................45 ACTION AND CLINICAL PHARMACOLOGY ............................................................45 STORAGE AND STABILITY ..........................................................................................49 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................50 PART II: SCIENTIFIC INFORMATION ................................................................................51 PHARMACEUTIC Read the complete document